🟢 A turning point in the US: in 2026, most major US insurers cover AHSCT for active MS after high-efficacy DMT failure, helping patients access treatment closer to home. Yet some still consider it investigational.
🟢 See the updated insurer-by-insurer overview at curems.net/procedure/#u...
